Clinical Study on Prostate Cancer
Men with a diagnosis of metastatic prostate cancer are being recruited for a national clinical trial currently under way at sites across the nation, including the Cancer Care Center at Bradford Regional Medical Center (BRMC), a network affiliate of Roswell Park Cancer Institute in Buffalo.
Because androgens -- testosterone and other male hormones -- cause prostate cancer cells to grow, some prostate cancer patients currently receive “androgen-deprivation” therapy to block the body’s production of androgens. Other prostate cancer patients are treated with docetaxel, a chemotherapy drug that either kills tumor cells or prevents them from dividing. This study is designed to determine whether the use of androgen-deprivation therapy and docetaxel together is more effective than androgen-deprivation alone.
Participants in this Phase III study will be randomly assigned to one of two groups. One group will receive androgen-deprivation therapy alone, and the other will receive androgen-deprivation therapy plus docetaxel.
Sponsored by the Eastern Cooperative Oncology Group (ECOG), the study will provide researchers with information critical to developing better treatments for prostate cancer.
Eyad S. Al-Hattab, M.D., medical director of Oncology/Hematology at BRMC's Cancer Care Center and staff physician in Medical Oncology at Roswell Park, will oversee the study at BRMC. As part of an affiliation agreement between BRMC and Roswell Park, Dr. Al-Hattab practices full-time in Bradford but also works with Roswell Park faculty to improve access to quality cancer care for patients in the southern tier of New York state and northwestern Pennsylvania.
For further information about the study, call Anne Zimbardi at BRMC at 814-362-8425 and refer to clinical trial ECOG-E3805.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, Roswell Park was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.
Because androgens -- testosterone and other male hormones -- cause prostate cancer cells to grow, some prostate cancer patients currently receive “androgen-deprivation” therapy to block the body’s production of androgens. Other prostate cancer patients are treated with docetaxel, a chemotherapy drug that either kills tumor cells or prevents them from dividing. This study is designed to determine whether the use of androgen-deprivation therapy and docetaxel together is more effective than androgen-deprivation alone.
Participants in this Phase III study will be randomly assigned to one of two groups. One group will receive androgen-deprivation therapy alone, and the other will receive androgen-deprivation therapy plus docetaxel.
Sponsored by the Eastern Cooperative Oncology Group (ECOG), the study will provide researchers with information critical to developing better treatments for prostate cancer.
Eyad S. Al-Hattab, M.D., medical director of Oncology/Hematology at BRMC's Cancer Care Center and staff physician in Medical Oncology at Roswell Park, will oversee the study at BRMC. As part of an affiliation agreement between BRMC and Roswell Park, Dr. Al-Hattab practices full-time in Bradford but also works with Roswell Park faculty to improve access to quality cancer care for patients in the southern tier of New York state and northwestern Pennsylvania.
For further information about the study, call Anne Zimbardi at BRMC at 814-362-8425 and refer to clinical trial ECOG-E3805.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, Roswell Park was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.
.jpg)
Comments